Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
17.08 USD | +0.18% | +4.72% | -45.45% |
Apr. 30 | UBS Adjusts ACADIA Pharmaceuticals' Price Target to $27 From $33, Keeps Buy Rating | MT |
Apr. 23 | Neuren Pharmaceuticals' Medication Secures Priority Review from Health Canada | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-45.45% | 2.82B | |
+26.28% | 48.09B | |
-3.99% | 40.43B | |
+46.73% | 40.62B | |
-6.20% | 28.36B | |
+6.36% | 24.89B | |
-21.47% | 19.01B | |
+27.58% | 12.09B | |
-2.75% | 11.8B | |
-2.02% | 11.88B |
- Stock Market
- Equities
- ACAD Stock
- News ACADIA Pharmaceuticals Inc.
- RBC Trims Price Target on ACADIA Pharmaceuticals to $35 From $36, Keeps Outperform Rating